Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals.

This study carried out an investigation into the pharmacokinetics and safety of the drug firocoxib in neonatal foals. It concluded that the drug was rapidly absorbed with minimal accumulation and found no significant negative effects when administered in repeated doses.

Research Methodology

• The study was conducted with seven healthy foals. Each was given a daily oral dose of 0.1 mg/kg firocoxib for nine consecutive days, starting when they were roughly 36 hours old.
• The researchers collected blood samples at specified intervals (0, 0.25, 0.5, 1, 2, 4, 8, 16, and 24 hours) after giving the first, fifth, and ninth doses of the drug. In between these dosages (doses 2, 3, 4, 6, 7, and 8) blood was also sampled just before the next dosage was administered.
• After the ninth dose, samples were collected at extended intervals (36, 48, 72, 96, 120, and 144 hours).
• These blood samples underwent high-pressure liquid chromatography with fluorescence detection to measure the levels of firocoxib.

Health and Safety Evaluation

• Multiple measures were taken to assess the safety and health of the foals. Physical examinations, body weight measurements, and gastroscopy were performed.
• The researchers also conducted complete blood counts, plasma biochemistry analyses, and urinalysis.

Findings

• The study found that firocoxib was rapidly absorbed into the bloodstream of the foals after oral administration, with minimal accumulation observed after repeated dosing.
• The terminal half-life of the drug was approximately 11 hours, meaning that around half of the drug had left the system after about 11 hours.
• 72 hours after administering the final dose, firocoxib was below the limit of detection (<2.5 ng/mL) in plasma samples. This suggests that by this point, most of the drug was cleared from the system.
• No significant abnormalities were observed in blood analyses, urinalysis, or gastroscopy, demonstrating firocoxib’s safety when administered at this dosage.

Conclusion

• This research concludes that firocoxib is absorbed quickly and passes through systems of neonatal foals without causing observable adverse effects.
• The study supports the use of firocoxib in treatment plans for foals, contributing to the body of evidence about the drug’s safety and efficacy in veterinary medicine.